SPARK Norway is the innovation program at the University of Oslo, and Grødeland is one of the principal investigators for a project in SPARK Norway. In brief, her project includes linking vaccine antigens to a targeting moiety that will direct antigens specifically to the immune cells most relevant for induction of protective immunity. The strategy has consistently enhanced immune responses in mice and larger animals, and is presently being prepared for a Phase I trial.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Norway
Year Founded:
Not applicable
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
Vaccine against pandemic influenza
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
